TriangleNeoadjuvant Therapy (NCT07762586)
Neoadjuvant Therapy trial for Bladder Cancer (NCT07762586). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–90 with luminal muscle-invasive bladder cancer, stage T2N0M0, who can receive systemic treatment and bladder removal. They must be ineligible for, or refuse, trimodality treatment.
The idea: gene testing identifies the luminal subtype. Patients are randomized to systemic treatment before bladder-removal surgery or directly to surgery. Researchers check whether pathology reveals more advanced cancer and measure tumor DNA. They are testing whether omitting preoperative treatment is safe for this group.
This phase 2 study plans 60 patients. Rutgers leads in New Brunswick, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.